April 27, 2017 4:07 PM ET


Company Overview of Marinus Pharmaceuticals, Inc.

Company Overview

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreemen...

170 North Radnor Chester Road

Suite 250

Radnor, PA 19087

United States

Founded in 2003

14 Employees



Key Executives for Marinus Pharmaceuticals, Inc.

Executive Chairman, Chief Executive Officer and President
Age: 59
Total Annual Compensation: $613.1K
Chief Financial Officer, Vice President, Treasurer and Secretary
Age: 45
Total Annual Compensation: $433.5K
Compensation as of Fiscal Year 2016.

Marinus Pharmaceuticals, Inc. Key Developments

Marinus Pharmaceuticals, Inc. Announces Lorianne K. Masuoka as Chief Medical Officer

Marinus Pharmaceuticals, Inc. announced that Lorianne K. Masuoka, MD has joined the company as Chief Medical Officer. As Chief Medical Officer, Dr. Masuoka will manage Marinus’ clinical programs in postpartum depression, status epilepticus and pediatric orphan indications with its positive allosteric modulator of GABA, ganaxolone. Dr. Masuoka recently served as Chief Medical Officer of InVivo Therapeutics, Cubist Pharmaceuticals and Nektar Therapeutic where as a member of executive management she oversaw and managed teams in the areas of clinical research, drug safety, biostatistics and data management, regulatory affairs, reimbursement and clinical operations. Previously, she has held various roles of increasing responsibility at Nektar Therapeutics, FivePrime Therapeutics, and Chiron.

Marinus Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Year Ended December 31, 2016

Marinus Pharmaceuticals, Inc. reported unaudited earnings results for the year ended December 31, 2016. For the period, the company reported net losses of $28.6 million and $24.9 million for the years ended December 31, 2016 and 2015, respectively. Cash used in operating activities was $24.8 million for the year ended December 31, 2016 compared to $20.1 million for the same period a year ago. Loss from operations was $28,242,000 against $24,432,000 a year ago. Net loss per share of common stock basic and diluted was $1.47 against $1.67 a year ago.

Marinus Pharmaceuticals, Inc. Announces Preclinical Data of Neuropharmacology

Marinus Pharmaceuticals, Inc. announced the publication of preclinical data in the January issue of Neuropharmacology, showing that its positive allosteric modulator of GABAA, ganaxolone ameliorates many of the behavioral abnormalities in a mouse model of adult Angelman syndrome (AS). Evidence from experimental models suggests that AS may be associated with deficient extrasynaptic GABAA receptor function. AS is a rare neurogenetic disorder characterized by severe developmental delay, motor impairments and epilepsy. The results showed that ganaxolone-treated mice exhibited improved anxiety measures, positive motor benefits, and reduced seizures with both short- and long-term treatment. Importantly, there was no tolerance to the antiseizure efficacy of ganaxolone or to its other therapeutic actions.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Marinus Pharmaceuticals, Inc., please visit www.marinuspharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.